Association of ranibizumab (Lucentis®) or bevacizumab (Avastin®) with dexamethasone and triamcinolone acetonide: An in vitro stability assessment

European Journal of Pharmaceutics and Biopharmaceutics

Volumn 78, Issue 2, 2011, Pages 271-277

  Veurink, Marieke ^a   Stella, Cinzia ^a   Tabatabay, Cyrus ^b   Pournaras, Constantin J ^b   Gurny, Robert ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

Aggregation state; Anti inflammatory drugs; Asymmetrical flow field flow fractionation; Monoclonal antibodies; Neovascular age related macular degeneration

Indexed keywords

BEVACIZUMAB; DEXAMETHASONE SODIUM PHOSPHATE; RANIBIZUMAB; TRIAMCINOLONE ACETONIDE;

ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIALYSIS; DRUG FORMULATION; DRUG STABILITY; DRUG STORAGE; FIELD FLOW FRACTIONATION; GEL PERMEATION CHROMATOGRAPHY; IN VITRO STUDY; LIGHT SCATTERING; PH; PROTEIN AGGREGATION; PROTEIN STABILITY; TEMPERATURE;

ANTIBODIES, MONOCLONAL; CHROMATOGRAPHY, GEL; DEXAMETHASONE; FRACTIONATION, FIELD FLOW; TRIAMCINOLONE ACETONIDE;

EID: 79955847228     PISSN: 09396411     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejpb.2010.12.018     Document Type: Article

References (26)

1. C.M. Andreoli, J.W. Miller, Anti-vascular endothelial growth factor therapy for ocular neovascular disease, Curr. Opin. Ophthalmol. 18 (2007) 502-508. (Pubitemid 351339405)
2. H. Dadgostar, N. Waheed, The evolving role of vascular endothelial growth factor inhibitors in the treatment of neovascular age-related macular degeneration, Eye 22 (2008) 761-767. (Pubitemid 351850511)
3. C.D. Regillo, D.M. Brown, P. Abraham, H. Yue, T. Ianchulev, S. Schneider, N. Shams, Randomized, double-masked, sham-controlled trial of ranibizumab for neovascular age-related macular degeneration: PIER study year 1, Am. J. Ophthalmol. 145 (2008) 239-248.
4. D.M. Brown, C.D. Regillo, Anti-VEGF agents in the treatment of neovascular age-related macular degeneration: applying clinical trials results to the treatment of everyday patients, Am. J. Ophthalmol. 144 (2007) 627-637.
5. A.J. Augustin, S. Puls, I. Offerman, Triple therapy for choroidal neovascularisation due to age-related macular degeneration: verteporfin PDT, bevacizumab and dexamethasone, Retina 27 (2007) 133-140.
6. S.M. Conti, P.J. Kertes, The use of intravitreal corticosteroids, evidence-based and otherwise, Curr. Opin. Ophthalmol. 17 (2006) 235-244.
7. L. Gopal, T. Sharma, Use of intravitreal injection of triamcinolone acetonide in the treatment of age-related macular degeneration, Indian J. Ophthalmol. 55 (2007) 431-435.
8. J.B. Jonas, Intravitreal triamcinolone acetonide: a change in a paradigm, Ophthal. Res. 38 (2006) 218-245.
9. A. Oliver, T.A. Ciulla, Corticosteroids as antiangiogenic agents, Ophthalmol. Clin. North Am. 19 (2006) 345-351. (Pubitemid 44279354)
10. H. Ahmadieh, A. Ramezani, N. Shoeibi, B. Bijanzadeh, A. Tabatabaei, M. Azarmina, M. Soheilian, G. Keshavarzi, M.R. Mohebbi, Intravitreal bevacizumab with or without triamcinolone for refractory diabetic macular edema; a placebo-controlled, randomized clinical trial, Graefes Arch. Clin. Exp. Ophthalmol. 246 (2008) 483-489.
11. H. Ahmadieh, R. Taei, M. Soheilian, M. Riazi-Esfahani, R. Karkhaneh, A. Lashay, M. Azarmina, M.H. Dehghan, S. Moradian, Single-session photodynamic therapy combined with intravitreal bevacizumab and triamcinolone for neovascular age-related macular degeneration, BMC Ophthalmol. 7 (2007) 7-10.
12. M. Colucciello, Intravitreal bevacizumab and triamcinolone acetonide combination therapy for exudative neovascular age-related macular degeneration: short-term optical coherence tomography results, J. Ocul. Pharmacol. Ther. 24 (2008) 15-24. (Pubitemid 351156638)
13. M. Soheilian, A. Ramezani, B. Bijanzadeh, M. Yaseri, H. Ahmadieh, M.H. Dehghan, M. Azarmina, S. Moradian, H. Tabatabaei, G.A. Peyman, Intravitreal bevacizumab (avastin) injection alone or combined with triamcinolone versus macular photocoagulation as primary treatment of diabetic macular edema, Retina 27 (2007) 1187-1195. (Pubitemid 350211523)
14. B. Demeule, R. Gurny, T. Arvinte, Where disease pathogenesis meets protein formulation: renal deposition of immunoglobulin aggregates, Eur. J. Pharm. Biopharm. 62 (2006) 121-130. (Pubitemid 43143264)
15. S. Hermeling, D.J. Crommelin, H. Schellekens, W. Jiskoot, Structure- immunogenicity relationships of therapeutic proteins, Pharm. Res. 21 (2004) 897-903.
16. A. Braun, L. Kwee, M.A. Labow, J. Alsenz, Protein aggregates seem to play a key role among the parameters influencing the antigenicity of interferon alpha (IFN-alpha) in normal and transgenic mice, Pharm. Res. 14 (1997) 1472-1478.
17. M. Bucciantini, E. Giannoni, F. Chiti, F. Baroni, L. Formigli, J. Zurdo, N. Taddei, G. Ramponi, C.M. Dobson, M. Stefani, Inherent toxicity of aggregates implies a common mechanism for protein misfolding diseases, Nature 416 (2002) 507-511. (Pubitemid 34288846)
18. H.C. Mahler, W. Friess, U. Grauschopf, S. Kiese, Protein aggregation: pathways, induction factors and analysis, J. Pharm. Sci. 98 (2009) 2909-2934.
19. B. Demeule, R. Gurny, T. Arvinte, Detection of Protein aggregates: Methodologies for Pharmaceutical Development, Thesis Dissertation, University of Geneva, 2006.
20. A. Martin, Physical Pharmacy, Physical Chemical Principles in the Pharmaceutical Sciences, fourth ed., 1993, pp. 178-179.
21. J.M. Moore, T.W. Patapoff, M.E. Cromwell, Kinetics and thermodynamics of dimer formation and dissociation for a recombinant humanized monoclonal antibody to vascular endothelial growth factor, Biochemistry 38 (1999) 13960-13967. (Pubitemid 29504227)
22. B. Demeule, M.J. Lawrence, A.F. Drake, R. Gurny, T. Arvinte, Characterization of protein aggregation: the case of a therapeutic immunoglobulin, Biochim. Biophys. Acta 1774 (2007) 146-153.
23. W. Fraunhofer, G. Winter, The use of asymmetrical flow field-flow fractionation in pharmaceutics and biopharmaceutics, Eur. J. Pharm. Biopharm. 58 (2004) 369-383. (Pubitemid 39037242)
24. E. Furrer, M. Berdugo, C. Stella, F. Behar-Cohen, R. Gurny, U. Feige, P.D. Lichtlen, D.M. Urech, Pharmacokinetics and posterior segment biodistribution of ESBA105, an anti-TNF-α single-chain antibody, upon topical administration to the rabbit eye, Invest. Ophthalmol. Vis. Sci. 50 (2009) 771-778.
25. W. Wang, S. Singh, D.L. Zeng, K. King, S. Nema, Antibody structure, instability, and formulation, J. Pharm. Sci. 96 (2007) 1-26.
26. E.Y. Chi, S. Krishnan, T.W. Randolph, J.F. Carpenter, Physical stability of proteins in aqueous solution: mechanism and driving forces in non native protein aggregation, Pharm. Res. 20 (2003) 1325-1336.